initi coverag arqul arql outperform rate
price target impress compani compet kinas inhibit
experienc manag team believ one-two punch compani
rare disease/oncolog franchis arq akt inhibitor blue-ski
scenario revers btk-inhibitor arq creat substanti valu
sharehold near- mid-term model arq constitut
share arql valuat sale arq anoth
share sale ascrib certainti market stage
development/data bullish arql
clinic data arq still earli stage phase on-going
collabor nation institut nih give us higher convict
akt pathway potenti key compon diseas
proteu phase studi run nih data complement on-going
phase trial run arql
conserv price arq us launch
high end oncology-lik price data arq rare
diseas strong believ price upsid potenti frame
refer cystic fibrosi medic price rang us
soliri price
arq believ potenti revers btk inhibitor versu
irrevers btk inhibitor current approv like ibrutinib acalabrutinib sell-
side consensu approv product assum sale
arql sunesi snss lead charg revers btk inhibit
believ execut critic molecul prosper
burgeon resist irrevers btk inhibitor woyach et al
increasingfrom percentag point per woyach et al nejm
resist per recent public woyach et al jco
believ revers btk inhibit constitut market opportun
beyond
arql expect present early-stag data three cohort eha
stockholm mid-jun expect data pk/pd profil arq data
btk knockdown biomark analysi side-effect report caution
data revers btk inhibit arql akt inhibitor still earli
commensur clinic develop risk impli
arqul develop target small
molecul therapeut treat cancer
rare diseas clinical-stag
pipelin consist five drug candid
target biomarker-defin patient
popul focu akt
focus identif
develop novel kinas inhibitor
analyst certif import disclosur see disclosur
arq approv variou rare diseas overgrowth syndrom
arq approv variou leukemia/lymphoma indic
arq continu demonstr potenti next-gener
akt inhibitor potenti advanc oncolog indic
initi coverag arqul arql outperform
rate price target impress compani
compet kinas inhibitor experienc manag team
believ one-two punch compani rare disease/oncolog
franchis arq akt inhibitor blue-ski scenario
revers btk-inhibitor arq creat substanti valu
sharehold next near- mid-term
reach recommend phase dose arq
initi pivot studi miransertib proteu syndrom
result nih sponsor phase
arq phase data solid tumor recommend
phase dose enter expans phase select tumor type
announc expans plan miransertib endometri
cancer
present arq phase data announc plan
announc clinic develop plan miransertib
present miransertib phase expans studi endometri
cancer announc futur plan
arq move quickli mid/lat stage develop next-
competitor arq revers btk inhibitor space fail
develop demonstr lengthen develop time vs
kinas inhibitor brought clinic arql
arq akt inhibit demonstr reduc potenti
variou rare diseas oncolog disord
arq demonstr potenti btk inhibit
analog ibrutinib/acalabrutinib
valu arq rare overgrowth diseas appli multipl estim ww sale discount
annual assum probabl market valu arq b-cell malign appli multipl
estim ww sale discount annual assum probabl market pipelin program
make remain price target
downsid risk outperform rate includ clinic failur arq arq phase trial later studi emerg
unaccept side effect failur show competit advantag versu product develop inabl advanc
strateg risk financ risk liquid small-capit risk
tabl content
valuat
product
manag biographi
initi coverag arqul arql outperform rate price
impress compani compet kinas inhibitor experienc
manag team believ one-two punch compani rare
disease/oncolog franchis arq blue-ski scenario revers
btk-inhibitor arq creat substanti valu sharehold next
arq rare overgrowth diseas like proteu
overgrowth spectrum model see exhibit approv
probabl
clinic data arq still earli stage phase
on-going collabor nation institut nih give us
higher convict akt pathway potenti key compon
diseas proteu phase studi run nih
data complement on-going phase
trial run arql
assum rare-diseas like fast uptak arq proteu
clove penetr five year post-launch
conserv price arq us
launch high end oncology-lik price data
arq variou overgrowth syndrom strong believ
price upsid potenti frame refer cystic fibrosi
medic vertex price rang us
soliri price
arq contribut arql valuat
arq believ potenti revers btk inhibitor
versu irrevers btk inhibitor current approv like ibrutinib
acalabrutinib sell-sid consensu product assum
sale beyond
burgeon resist irrevers btk inhibitor woyach
et al increasingfrom percentag point per woyach et al
sale imbruvica sale imbruvica sale calquenc sale calquenc sale acalabrutinib launch octob pharmacyclics/janssen collabor share imbruvica ibrutinib net profit develop cost compani joint co-exclus right commerci us effort led commerci ex-u arql outperform
nejm resist per recent public
woyach et al jco believ revers btk
inhibit constitut market opportun beyond
arql expect present earli stage data three cohort eha
stockholm mid-jun expect data pk/pd profil
arq data btk knockdown biomark analysi side-effect
would caution patient arq fail multipl
line therapi fragil patient prone progress
sunesi snss arql lead charg revers btk
inhibit believ execut critic manag
team molecul prosper potenti
revers btk inhibit larg enough space zero-
assum arql take preval btk resist patient
market share time-frame newli diagnos
lymphoma/leukemia patient popul time-frame
assum minor differ snss arql product profil
lead minim differ mid/lat stage clinic data key
clinic develop execut variou tumor type
assum price arq upon launch believ
upsid assumpt
arq contribut valuat
real potenti arq potenti next-gener akt
inhibitor constitut valuat
earli phase data present md anderson suggest
arq may better therapeut window arq
potenti akt inhibitor develop
arql current work toward reach maximum toler dose
studi plan analyz full phase dataset
earli decid whether arq best akt inhibitor
take forward oncolog
await clariti data clinic develop path arq
expand model expect arql explor singl
agent activ phase ultim move combin
valu arq rare overgrowth diseas appli multipl
estim ww sale discount annual assum
probabl market valu arq b-cell malign appli
multipl estim ww sale discount annual assum
probabl market pipelin program make remain
price target
downsid risk outperform rate includ clinic failur arq
arq phase trial later studi emerg unaccept side effect failur
show competit advantag versu product develop inabl
advanc pipelin product
small-capit risk
productww sale yeardiscount ratesal multipleprob ketnpvrisk-adj npvcommentsarq rate roe nbi index bbg arq approv us ex-usarq rate roe nbi index bbg arq approv us forma cash end akt inhibitor oncologytot arql outperform
arql found biopharmaceut compani engag research
develop innov therapeut treat cancer rare diseas compani
focus discoveri develop commerci novel small molecul
drug area high unmet need compani also util biomark
indic particular biolog condit process may predict clinic benefit
compound defin patient popul
arql long histori kinas drug discoveri develop discov
introduc ten kinas inhibitor clinic trial compani current clinic
pipelin consist five product candid target patient
popul arql product candid direct toward molecular target
biolog process demonstr role develop human cancer
rare non-oncolog diseas program develop
current proprietari clinic pipelin candid follow
miransertib arq select inhibitor akt serine/threonin kinas
phase rare overgrowth diseas phase rare diseas
proteu syndrom partnership nation institut
nih also phase oncolog combin hormon therapi
arq oral bioavail potent revers inhibitor wild
type btk phase b-cell malign refractori
therapeut option
arq next-gener inhibitor akt phase solid tumor
harbor mutat
arq arq intraven administ analogu
lapachon natur exist substanc arq pro-drug arq
demonstr vitro activ wide rang solid tumor
phase test singl agent arq anti-canc activ measur
tumor respons occur exclus portion patient high level
arql recent partner derazantinib arq basilea up-front
payment anoth mileston plu royalti tier singl digit mid-
note arql advanc pipelin candidatetivantinibha met
failur phase trial earli spite intrigu phase
tivantinib result highlight concern around small-molecul drug
develop highli target therapi work well small popul earli
clinic trial overwhelm larger-later-stag trial issu uniqu
arql believ
product develop
miransertib arq investig oral avail select pan-akt inhibitor
potent inhibit isoform drug current phase
oncolog phase proteu syndrom rare over-growth diseas trial
conduct nation institut nih trial biomarker-driven
focus enrol patient mutat
arql initi compani sponsor phase trial overgrowth diseas includ
overgrowth spectrum proteu syndrom
miransertib suppress akt pathway via two mode action
bind inact form akt miransertib prevent membran
local full akt activ
miransertib also directli inhibit membran associ activ form
earli becam appar akt/pkb serine/threonin protein
kinas function critic regul cell surviv prolifer song
akt/pkb famili compris three highli homolog member known
mammalian cell signal
transduct pathway promot surviv growth respons extracellular
signal protein involv phosphatidylinositol akt protein
prolifer cell migrat angiogenesi phosphoryl rang intracellular
protein pathway highli regul multipl mechan often involv
crosstalk signal pathway
problem pathway regul lead increas signal activ
link rang diseas akt phosphoryl mani differ
substrat lead wide rang effect cell
akt pathway abnorm activ implic multipl oncogen
process cell prolifer apoptosi pathway emerg target
potenti therapeut relev compound inhibit activ
link varieti cancer well select non-oncolog indic pre-clin
research demonstr miransertib potent select inhibit
activ inact form akt
landmark discoveri research nation genom research
institut demonstr somat mutat oncogen carri
set instruct produc kinas caus proteu syndrom point
mutationa single-lett misspel dna genet codein gene
activ tissu growth characterist proteu syndrom
diseas oncolog
proteu syndrom rare condit character overgrowth bone skin
tissu organ tissu affect diseas grow proport
rest bodi overgrowth usual asymmetr mean affect right
left side bodi differ newborn proteu syndrom
sign condit overgrowth becom appar age
month get sever age
proteu syndrom rare condit incid less million peopl
world-wide hundr affect individu report medic
overgrowth diseas term use refer spectrum rare diseas identifi
somat mutat often pathway result excess growth
certain area bodi individu diseas fall within overgrowth
spectrum similar symptom diseas defin uniqu characterist
diseas part overgrowth spectrum includ diseas
relat overgrowth spectrum proteu syndrom
paper publish novemb keppler-noreuil et al genet
semin genet dec highlight
signal pathway play essenti role
regul normal cell growth metabol surviv somat activ mutat
pathway amongst common mutat identifi
cancer shown caus spectrum overgrowth syndrom includ
overgrowth spectrum proteu syndrom brain overgrowth
condit clinic find disord may isol multipl includ
sporad mosaic overgrowth adipos skelet muscl brain vascular lymphat
skin abnorm includ epiderm nevi hyper- hypopig lesion
potenti risk tumorigen
dysregul pathway implic cancer sever
small molecul inhibitor target differ compon signal
pathway clinic investig develop therapi bring closer
prospect target treatment somat overgrowth
driven cancer preval mutat cancer vari
depend tumor type tumor type highest preval
mutat breast bladder endometri ovarian cervic cancer
current miransertib arq four clinic trial
studi arq patient overgrowth diseas and/or vascular
accord clinic trial websit open label phase studi arq
administ oral primari object studi assess safeti arq
subject least year age overgrowth diseas and/or vascular
anomali document genet alter pathway
dose find trial arq children adult proteu syndrom
accord clinic trial websit proteu syndrom ps caus mutat
gene gene make protein commun protein
bodi make cell grow mutat chang chemic signal bodi
caus overgrowth ps fatal drug arq reduc signal
protein may reduc stabil overgrowth peopl ps
research want find best dose arq base effect tissu
peopl ps
exhibit proteu trial
phase dose escal studi arq adult subject advanc
solid tumor recurr malign lymphoma clinicaltri gov identifi
accord clinic trial websit open-label phase dose escal
studi oral arq administ subject advanc solid tumor recurr
malign lymphoma studi design explor safeti toler
pharmacokinet pharmacodynam arq defin recommend
phase dose arq
open-label phase studi arq combin carboplatin plu
paclitaxel combin paclitaxel combin anastrozol
accord clinic trial websit open-label phase dose escal
studi oral arq administ combin carboplatin plu paclitaxel
carboplatin paclitaxel arm combin paclitaxel alon paclitaxel arm
subject advanc inoper metastat and/or recurr solid tumor
combin anastrozol anastrozol arm subject ovarian endometri
cancer subject endometri cancer enrol expans cohort
anastrozol arm
arq investig oral avail select next gener pan-akt
inhibitor potent inhibit isoform distinct properti
miransertib arq arq could provid advantag clinic develop
focus akt inhibit
exhibit propertiesakt inhibitor arq arq
yu savag eathiraj mead wick mj et al target pathway alloster
arq suppress akt pathway via two mode action
bind inact form akt arq prevent membran
local full akt activ
arq also directli inhibit membran associ activ form
arq similar mechan action moa arq certain
distinct advantag arq akt inhibitor develop
yu savag eathiraj mead wick mj et al target pathway alloster akt
phase biomark driven trial cancer akt mutat commenc
arq solid tumor genet alter activ
mutat -null known action mutat
accord clinic trial websit open-label phase dose escal
studi arq administ oral subject advanc solid tumor
genet alter activ mutat pten-nul known action
arq investig oral bioavail potent revers inhibitor
wild-typ bruton tyrosin kinas btk arql commenc phase
trial patient b-cell malign refractori therapeut option juli
resist ibrutinib identifi year ago note
small proport cll patient observ relaps ibrutinib
treatment mechan resist irrevers kinas inhibitor resist
associ btk inhibit elucid report new england
journal medicin woyach et al identifi mutat confer resist
ibrutinib cll
recent academ research suggest ibrutinib resist might high
ibrutinib treat popul target bruton tyrosin
kinas btk ibrutinib chronic lymphocyt leukemia led paradigm shift
therapi relaps uncommon current follow-up acquir mutat
btk caus relaps data regard preval natur histori
mutat limit patient accru four sequenti studi ibrutinib
includ analys deep sequenc btk perform
retrospect patient experienc relaps prospect screen
popul result median follow-up time year estim cumul
incid progress year ci ja woyach et al
believ increas usag ibrutinib variou leukemia lymphoma
indic recent approv acalabrutinib potenti btk resist
irrevers btk inhibitor increas
ibrutinib acalabrutinib coval binder btk irrevers inhibitor arq
vecabrutinib revers btk inhibitor among next wave btk
inhibitor develop believ revers btk inhibitorsassum good
phase risk/benefit profilewil serv high unmet need patient escap
revers btk inhibitor like ibrutinib acalabrutinib
accord wu et al journal hematolog oncolog ibrutinib
first-in-class highli potent small molecul inhibitor select bind cystein
residu alloster inhibitori segment btk kinas domain compound
irrevers abrog full activ btk inhibit autophosphoryl
tyrosin residu addit resist ibrutinib observ
result second-gener btk inhibitor develop estim progression-
free surviv rate among relapsed/refractori cll patient treat ibrutinib
report month mechan acquir resist ibrutinib
activ investig
one observ case mutat ibrutinib observ wu et al
one case report cll patient develop resist month ibrutinib dose
high mg daili sequenc rna pre- post-treat sampl
thymidine-to-adenin mutat nucleotid btk complementari dna
cdna discov led substitut serin cystein residu
ibrutinib form coval bond sulfhydryl group btk
irrevers inhibit kinas activ btk new amino acid residu prevent
ibrutinib coval bind btk mutant convert irrevers inhibit
btk revers inhibit phosphoryl tyrosin residu
studi half-maxim inhibitori concentr ibrutinib chang nm
mutant btk nm non-mut btk mutat
detect level ibrutinib-nav patient suggest mutant clone
select btk inhibit ibrutinib btk mutat also
found respons acquir resist ibrutinib mcl underlin
exhibit ibrutinib progressionincid surviv
woyach et al note jco articl btk mutat
frequenc ibrutinib resist patient observ author
phase trial patient b-cell malign refractori therapeut option
initi juli phase portion trial dose escal
studi open refractori patient aim establish recommend dose
upon complet phase trial arql plan begin phase portion
trial consist number expans cohort includ patient
mutat refractori approv therapi goal phase portion
would establish proof concept earli sign activ
arql commenc phase trial patient b-cell malign refractori
therapeut option juli
safeti pk pd antitumor activ arq hematolog
accord clinic trial websit phase dose escal studi evalu
safeti pharmacolog activ arq subject relaps refractori
hematolog malign dose oral per day begin mg/dose week
follow cohort treat escal dose dose limit toxic
recommend phase dose reach
dose escal period intra-subject dose escal permit
follow criteria met
next higher dose regimen demonstr safe least
subject last subject complet one cycl without experienc
subject receiv dose escal experienc dlt
determin expand cohort studi specif malign b-
cell nhl wm cll open explor safeti
pharmacolog activ arq monotherapi
compani also pursu approach fgfr inhibit outlin
exhibit well product develop cholangiocarcinoma relat
variou compani develop akt inhibitor outlin exhibit
also number inhibitor mtor kinas pathway
number compani current develop product btk
inhibit notabl revers btk inhibitor current develop b-cell
malign includ snss outperform loxo outperform
exhibit kinas inhibit profilebtk inhibitor develop
productcompanyproductdevelop fgfr tumorsbayerrogaratinib tumorsbioclin cancerdebiopharm groupdebio tumorsboehring ingelheim nintedanibphas tumorseisai co lenvatinibphas tumorsf prime therapeuticsbemarituzumabphas cancerincyt cancer/cholangiocarcinomajohnson johnsonerdafitinibphas cancerbridgebioinfigratinibphas tumorsserviermet/axl/fgfrphas cancertaiho tumorstakeda pharmaceuticalsivosidenibphas pharma lung cancerdainippon sumitomo systemsphp therapyphas akt cancer tumorsmerck tumorsnovarti hematolog cancersrexahn archexin preclinicalliv cancerrocheipatasertib scienceszydelig idelalisib approvedcl fl sllnovarti agafinitor everolimu approvedbreast kidney cancer organ transplantpfizertorisel temsirolimu approvedren cell carcinoma rcc pfizerrapamun rapamycin approvedkidney transplantaptos malignanciesloxo malignanciesabbvieimbruvicaapprovedb-cel malignanciesabbvievenclexta venetoclax approvedcllastrazenecacalqu acalabrutinib approvedmclbeigenezanubrutinibphas kgaaevobrutinibphas sclerosi lupus disordersgileadtirabrutinibphas malignanciesprincipia wild-typ btk btk inhibit derazantinib fgfr inhibitor icca arql outperform
four issu patent us cover composit matter lead
akt compound expir date rang decemb june
grant patent eu australia peopl republ china hong
kong israel japan south korea mexico malaysia macau new zealand
philippin republ singapor russia taiwan south africa
patent expir june
three issu patent us relat synthesi polymorph
lead akt compound expiri rang march april
one issu patent us cover composit matter lead fgfr
compound patent adjust beyond normal expir date
decemb januari
grant patent eu australia peopl republ china israel
japan south korea taiwan philippin mexico macau south africa
patent expir decemb
numer file composit matter patent applic variou countri
one issu patent us cover composit matter
compound pharmaceut composit contain compound
therapeut use compound treatment cancer us patent
trademark offic determin term patent adjust beyond
normal expir date april decemb
issu patent eu australia peopl republ china canada
hong kong mexico taiwan cover composit matter
compound expir april
one issu patent us cover composit matter arq
pharmaceut composit compris arq expir date
patent decemb
file patent applic us foreign jurisdict cover
analog arq applic issu patent expir
august
arql maintain issu patent cover composit matter
pharmaceut composit method use formul manufactur
combin anti-cancer agent us foreign territori
mr pucci join arqul chief execut offic member board june
bayer serv senior vice presid presid charg
bayer-sch pharmaceut global oncology/speci
busi unit previous mr pucci senior vice presid
global specialti busi presid oper
member bayer pharmaceut global manag committe bayer mr
pucci involv broad rang activ relat nexavar sorafenib oral
multipl kinas inhibitor use treat liver kidney cancer activ includ
market mr pucci join bayer head italian pharmaceut oper
prior bayer mr pucci held posit increas respons
culmin appoint manag director eli lilli sweden ab lilli
respons includ oper sale market strateg plan novemb
mr pucci appoint board director dyax corp serv
independ director member audit committe chairman govern
nomin committe acquisit dyax shire januari april
appoint board director algeta asa oncolog compani
base oslo norway serv independ director member
audit committe acquisit algeta bayer also director
newlink genet corp sinc novemb septemb mr pucci
elect board director west servic inc
intern manufactur packag compon deliveri system inject
drug healthcar product mr pucci hold univers chicago
graduat universit degli studi di napoli napl itali
mr lawrenc join arqul april pod hold ltd intern ventur
capit firm co-found recent serv gener
partner help drive strateg growth firm includ deal sourc
structur syndic busi expans activ serv presid
us subsidiari mr lawrenc serv lead partner invest activ number
compani includ cancer compani public financ
experi includ initi public offer numer financ america on-line
inc aol well public financ human genom scienc hybridon
mani compani work numer merger acquisit includ
aol/tim warner roche/compuchem steinway piano dec/intel mitotix/gpc
previous mr lawrenc attorney partner mintz levin cohn
ferri glovski popeo mintz levin serv extern
corpor counsel public privat compani manag transact legal practic
provid strateg guidanc client period rapid growth
transform corpor event mr lawrenc work gaston
firm corpor law depart hold bachelor degre amherst
colleg boston univers school law
dr schwartz join arqul chief medic offic juli took
respons head research develop dr schwartz
decad experi pharmaceut biotechnolog industri prior join
arqul senior vice presid clinic regulatori affair chief medic
offic built led clinic regulatori qualiti
assur depart respons develop new cancer drug
prior ziopharm dr schwartz held number posit bayer healthcar
experi oncolog encompass clinic develop novel cytostat
cytotox immunolog agent bayer dr schwartz key physician
respons global clinic develop sorafenib nexavar led clinic
team success phase trial renal cell cancer lead food
drug administr fda approv extens regulatori experi work
fda oncolog divis european medicin agenc ema numer
health author dr schwartz also respons clinic
regulatori activ includ phase studi interact nation cancer
institut oncolog cooper group dr schwartz receiv medic
degre univers pretoria south africa practic medicin work
univers toronto prior career industri
mr weiskopf join arqul februari vice presid financ corpor
control treasur promot chief offic treasur
may prior mr weiskopf chief offic awar inc
director financ lightbridg inc held
number financi manag posit increas respons digital/compaq
comput corpor year began career work ernst young llp
five year mr weiskopf also part-tim instructor boston univers
program mr weiskopf certifi public account hold magna cum
laud account univers massachusett amherst
namepositionyearsalari stock award option award incent compens compens paolo lawrencepresid brian name execut offic amount includ compani contribut plan account execut payment group term life insur long-term disabl amount column includ compens earn defer elect name execut offic compani retir save plan establish section tax code column reflect aggreg grant date fair valu option award grant fiscal year assumpt use calcul amount includ note compani audit financi statement year end decemb includ compani annual report addit inform regard stock option issu name execut offic provid tabl outstand equiti award fiscal year-end bonu amount earn annual incent program paid first quarter addit inform regard annual incent program provid compens discuss analysisperformance-bas bonus arqul inc
miransertib arq modelmiransertib arq assumptionscommentspopul unit us/eu combin popul address popul wwovergrowth diseas usproteu preval incid live birthsmadelung incid live birthsneurofibromatosi type incid live diseas euproteu preval incid live birthsmadelung preval eu mediterranean countri assum incid live birth south euneurofibromatosi type incid live diseas rowproteu preval incid live birthsmadelung type incid live rate assumptionspric per discount us discount us pricepric assumptionsintellectu arql outperform
statesovergrowth diseas type penetrationproteu type type revenu type arqul inc
diseas type penetrationproteu type type revenu type arql outperform
diseas type penetrationproteu type type revenu type revenu arqul inc
arq modelarq lymphoma/leukemia marketdiagnosedcll/sl line line patient progress timemcl nhl caseswaldenstrom macroglobulinemia wm cancer societydlbcl stat roch ir slidesfollicular lymphoma stat roch ir imbruvica sale product imbruvica sale product salesavg cost imbruvica treatment assumpt average cost treatment across indic imbruvica treat imbruvica treat arq assumptionmortality/progression/dropout per assumptionex-u marketdiagnosedcll/sl line ex-u market develop us diagnosedcll/sl line macroglobulinemia wm lymphoma imbruvica sale product imbruvica sale product salesavg cost imbruvica treatment assumpt ex-u market us imbruvica treat imbruvica treat arq per assumptionperc mutat revenu marketpreval imbruvica treat lymphoma/leukemia mutat mutat penetr penetr preval incid arq revenu marketpreval imbruvica treat lymphoma/leukemia mutat mutat penetr penetr preval incid arq revenu arq arql outperform
arqul statement million except per share sales- research develop total research gener administr restructur costs- total oper oper interest interest expense- incom total incom loss incom unreal gain market securities- provis incom taxes- net incom dilut share outstand arqul inc
arqul balanc cash market secur short prepaid expens current total current market secur long term- properti equip total account payabl accru note payable- current portion defer current portion defer gain sale leaseback- total current defer revenu net current portion- defer gain sale leaseback net current portion- note payable- warrant liability- total prefer stock- common addit paid-in accumul comprehens accumul total sharehold total liabil sharehold arql outperform
stock price compani mention report
